GenSpy
The S&P Specialist
New
Our S&P 500 strategy, with strong risk-adjusted returns in backtesting since 2019.
- CAGR
- 66.3%
- Max drawdown
- 23.7%
- Sharpe ratio
- 1.67
Jan 1, 2019 – Oct 31, 2026. All results are from a backtest. Trades leveraged ETFs. Price: $100 per month.
Our steady strategy, with the smallest drawdown of our published strategies in backtesting.
- CAGR
- 33.4%
- Max drawdown
- 8.1%
- Sharpe ratio
- 1.82
Jan 1, 2019 – Oct 31, 2026. All results are from a backtest. Price: $50 per month.
GenConfluence
The Balancer
New
Our balanced strategy, pairing the Nasdaq-100 with gold.
- CAGR
- 28.8%
- Max drawdown
- 13.8%
- Sharpe ratio
- 1.35
Jan 1, 2019 – Oct 31, 2026. All results are from a backtest. Price: $50 per month.
Our flagship strategy that has demonstrated strong risk-adjusted returns in backtesting over the long‑term.
- CAGR
- 95.1%
- Max drawdown
- 23.4%
- Sharpe ratio
- 1.97
Jan 1, 2019 – Oct 31, 2026. Backtested through 2025; 2026 reflects live signals. Trades leveraged ETFs. Waitlisted — join the waitlist for access.
Our high-flyer strategy for daring souls, with higher returns than The Champion in our published results.
- CAGR
- 118.5%
- Max drawdown
- 21.1%
- Sharpe ratio
- 2.07
Jan 1, 2019 – Oct 31, 2026. Backtested through 2025; 2026 reflects live signals. A high-risk strategy. Trades leveraged ETFs. Waitlisted — join the waitlist for access.
Strategy descriptions refer to our published backtested and live results; they are not a promise of future performance. Past performance does not guarantee future results.